Purple Biotech (PPBT) ehemals KTOV (Mkap $16 M) ( Cash $17 M) US Zulassungsantrag diesen Quartal (Seite 100)
eröffnet am 18.07.17 17:14:19 von
neuester Beitrag 04.06.24 19:51:10 von
neuester Beitrag 04.06.24 19:51:10 von
Beiträge: 1.798
ID: 1.257.452
ID: 1.257.452
Aufrufe heute: 0
Gesamt: 149.448
Gesamt: 149.448
Aktive User: 0
ISIN: US74638P1093 · WKN: A2QLTP · Symbol: PPBT
0,6100
USD
-1,37 %
-0,0085 USD
Letzter Kurs 15.06.24 Nasdaq
Neuigkeiten
| TitelBeiträge |
|---|
01.06.24 · globenewswire  |
21.05.24 · globenewswire |
25.04.24 · globenewswire |
28.03.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,8000 | +2.566,67 | |
| 3,3000 | +44,74 | |
| 1,2200 | +31,76 | |
| 1,2450 | +29,69 | |
| 7,7600 | +29,33 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,7900 | -24,80 | |
| 1,0100 | -26,81 | |
| 9,5300 | -34,00 | |
| 1,2400 | -34,39 | |
| 1,0950 | -34,43 |
Beitrag zu dieser Diskussion schreiben
Feedback
..... newly released proof-of-concept data showing evidence of NT-219 mechanism of action in REVERSING cancer drug resistance in PDX models. The data was presented in a poster at the American Association for Cancer Research's (AACR) Pancreatic Cancer: Advances in Science and Clinical Care conference in Boston on September 8, 2019.
https://www.streetinsider.com/dr/news.php?id=15894765
NT-219 is a first-in-class small molecule bi-specific inhibitor of two key cancer resistance pathways STAT3 and IRS1/2. As previously disclosed, the preclinical study initially evaluated the efficacy of NT-219 in combination with the approved chemotherapy agent gemcitabine on four PDX models of mutated KRAS pancreatic cancer. Data demonstrated reversal of gemcitabine-resistant tumors in all PDX models following treatment with NT-219 and gemcitabine. One of these models demonstrated complete response in about half of the animal group upon addition of NT-219 to gemcitabine. The study was then extended to define an optimal dose regimen and future clinical protocol.
Newly released data from the NT-219 poster showed:
The combination of NT-219 with the targeted therapies trametinib (MEK inhibitor) or folfirinox (chemotherapy) reversed tumor resistance to the treatments.
Administering NT-219 prior to chemotherapy suppressed activation of two key cancer survival pathways, STAT3 and IRS. The sequence of administering the therapies had a remarkable impact on the efficacy of NT-219 in reversing resistance.
Gene expression analysis of the tumors in a PDX model of KRAS mutated pancreatic cancer revealed an average 80% reduction in IRS1 levels compared to the control group following a single treatment with NT-219 and gemcitabine combined therapy. Similar reductions were observed in the expression of STAT3-regulated genes and the proliferation marker Ki67, confirming NT-219 mechanism of action.
A dose-dependent therapeutic effect of NT-219 was demonstrated on tumor-growth and correlated with NT-219 levels in plasma.
“STAT3 and IRS play an important role in KRAS-induced pancreatic tumorigenesis and drug resistance. Demonstrating efficacy of NT-219 in pancreatic cancer models is in line with previous results in other cancer types. We believe that targeting IRS and STAT3 may be a tumor-agnostic solution to combat resistance to multiple oncology drugs," said Hadas Reuveni, PhD, VP Research and Development of Kitov. "NT-219 is a first-in-class small molecule which suppresses both targets using a unique mechanism of action, and is crucial for overcoming cancer drug resistance."
“We are encouraged by the results of the study which demonstrate the potential of NT-219 to reverse resistance to oncology therapies in a wide range of PDX models. We plan to clinically explore its efficacy in multiple hard-to-treat oncology indications including squamous cell carcinoma of the head and neck in a planned clinical study to be launched soon. We are also exploring its potential in pancreatic cancer,” said Isaac Israel, CEO of Kitov. “Resistance to chemotherapy and targeted therapies is a major problem facing oncology patients. Kitov is now strategically focused on developing first-in-class oncology therapies, including such which are targeted to overcome drug resistance and tumor immune evasion, and to ultimately provide patients long-lasting treatment alternatives.”
Kitov plans to submit an Investigational New Drug Application (IND) to the U.S Food and Drug Authority (FDA) for a clinical study on NT-219 in combination with cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck before the end of 2019, and to initiate the trial immediately following FDA’s clearance.
The poster is available on the “Investor Relations” section on the Kitov website: http://kitovpharma.investorroom.com/index.php?s=151
https://www.streetinsider.com/dr/news.php?id=15894765
NT-219 is a first-in-class small molecule bi-specific inhibitor of two key cancer resistance pathways STAT3 and IRS1/2. As previously disclosed, the preclinical study initially evaluated the efficacy of NT-219 in combination with the approved chemotherapy agent gemcitabine on four PDX models of mutated KRAS pancreatic cancer. Data demonstrated reversal of gemcitabine-resistant tumors in all PDX models following treatment with NT-219 and gemcitabine. One of these models demonstrated complete response in about half of the animal group upon addition of NT-219 to gemcitabine. The study was then extended to define an optimal dose regimen and future clinical protocol.
Newly released data from the NT-219 poster showed:
The combination of NT-219 with the targeted therapies trametinib (MEK inhibitor) or folfirinox (chemotherapy) reversed tumor resistance to the treatments.
Administering NT-219 prior to chemotherapy suppressed activation of two key cancer survival pathways, STAT3 and IRS. The sequence of administering the therapies had a remarkable impact on the efficacy of NT-219 in reversing resistance.
Gene expression analysis of the tumors in a PDX model of KRAS mutated pancreatic cancer revealed an average 80% reduction in IRS1 levels compared to the control group following a single treatment with NT-219 and gemcitabine combined therapy. Similar reductions were observed in the expression of STAT3-regulated genes and the proliferation marker Ki67, confirming NT-219 mechanism of action.
A dose-dependent therapeutic effect of NT-219 was demonstrated on tumor-growth and correlated with NT-219 levels in plasma.
“STAT3 and IRS play an important role in KRAS-induced pancreatic tumorigenesis and drug resistance. Demonstrating efficacy of NT-219 in pancreatic cancer models is in line with previous results in other cancer types. We believe that targeting IRS and STAT3 may be a tumor-agnostic solution to combat resistance to multiple oncology drugs," said Hadas Reuveni, PhD, VP Research and Development of Kitov. "NT-219 is a first-in-class small molecule which suppresses both targets using a unique mechanism of action, and is crucial for overcoming cancer drug resistance."
“We are encouraged by the results of the study which demonstrate the potential of NT-219 to reverse resistance to oncology therapies in a wide range of PDX models. We plan to clinically explore its efficacy in multiple hard-to-treat oncology indications including squamous cell carcinoma of the head and neck in a planned clinical study to be launched soon. We are also exploring its potential in pancreatic cancer,” said Isaac Israel, CEO of Kitov. “Resistance to chemotherapy and targeted therapies is a major problem facing oncology patients. Kitov is now strategically focused on developing first-in-class oncology therapies, including such which are targeted to overcome drug resistance and tumor immune evasion, and to ultimately provide patients long-lasting treatment alternatives.”
Kitov plans to submit an Investigational New Drug Application (IND) to the U.S Food and Drug Authority (FDA) for a clinical study on NT-219 in combination with cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck before the end of 2019, and to initiate the trial immediately following FDA’s clearance.
The poster is available on the “Investor Relations” section on the Kitov website: http://kitovpharma.investorroom.com/index.php?s=151
Es scheint so, dass VCNX mit seinem VX15 NICHT an die Leistungsdaten von NT219 herankommt in den ersten Studien...
Quelle: https://immuno-oncologynews.com/vx15/
Komisch, dass Merck nicht mit Kitov weitergemacht hat.... oder gab es einen anderen Grund??? :-)
Quelle: https://immuno-oncologynews.com/vx15/
Komisch, dass Merck nicht mit Kitov weitergemacht hat.... oder gab es einen anderen Grund??? :-)
Vaccinex Announces Clinical Collaboration with Merck to Evaluate Pepinemab in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Merck hat sich VCNX geschnappt... mal schauen, was Lilly macht....... mein Tipp ist nach wie vor der kommenden Montag. Das eben gepostete Video (https://www.webcaster4.com/Webcast/Page/2495/37334 ) sollte man sich mal ab Minute 14 anhören....
hmmm.. https://finance.yahoo.com/news/vaccinex-announces-clinical-c…
Merck hat sich VCNX geschnappt... mal schauen, was Lilly macht....... mein Tipp ist nach wie vor der kommenden Montag. Das eben gepostete Video (https://www.webcaster4.com/Webcast/Page/2495/37334 ) sollte man sich mal ab Minute 14 anhören....
hmmm.. https://finance.yahoo.com/news/vaccinex-announces-clinical-c…
Antwort auf Beitrag Nr.: 65.111.818 von kartman am 17.09.20 15:42:38no....
https://www.globenewswire.com/news-release/2020/03/12/199946…
da müsst es schon ein Katastrophe geben..
Verträge und Zulassungen durch Krankenkassen.... Studien usw.. Schau mal auf den vorherigen Seiten..
Die GENAUEN Zahlen fehlen natürlich noch und wir warten auf das Reporting...
https://www.globenewswire.com/news-release/2020/03/12/199946…
da müsst es schon ein Katastrophe geben..
Verträge und Zulassungen durch Krankenkassen.... Studien usw.. Schau mal auf den vorherigen Seiten..
Die GENAUEN Zahlen fehlen natürlich noch und wir warten auf das Reporting...
Antwort auf Beitrag Nr.: 65.098.507 von Sven_Bonn am 16.09.20 15:11:48Consensi kann auch floppen. Wer weiß das zurzeit schon? Von geplanten Umsätzen halte ich nicht viel.
Trading Spotlight
Du nervst nicht, deine Beiträge sind gut recherchiert und interessant. Man hat nur das Gefühl, dass du dich in Kitov verliebt hast und täglich enttäuscht bist, dass die Aktie nicht nach oben explodiert. Biotech heißt Geduld haben und du bist doch überzeugt von der Firma. Gut Ding braucht Weile. Ich bin sich investiert und ca. 15% in den Miesen. Es kann durchaus noch weiter runtergehen, aber eine gute Meldung und die Aktie kann 100% nach oben springen und ich glaube fest daran, dass gute Meldungen kommen werden, morgen, in einer Woche oder in ein paar Monaten, das ist mir egal.
"$KTOV everything the Lily CFO said yesterday and so far today indicates an acquisition in the oncology field.. then all the things that line up with NT-219.. In phase 1, small molecule mutation blocker.."
... jetzt nerve ich nicht mehr.... :-)
... jetzt nerve ich nicht mehr.... :-)
Interessant!
even if you're short on ktov(dumb) you should listen to the Lilly CFO talking about small molecule mutation blockers and the market outlook for them. The guy understands the market better than you do and all of that applies to kitov directly. Only 26 minutes.
--> Link: https://www.webcaster4.com/Webcast/Page/2495/37334
even if you're short on ktov(dumb) you should listen to the Lilly CFO talking about small molecule mutation blockers and the market outlook for them. The guy understands the market better than you do and all of that applies to kitov directly. Only 26 minutes.
--> Link: https://www.webcaster4.com/Webcast/Page/2495/37334
.. und noch kurze eine Info aus stocktwits:
"LLY CFO stating they are looking for early stage clinical and preclinical first in class assets to bolster their pipeline for 2025-2035 in major departments like Oncology.
Interesting because I was told by the Stocktwits scientist nobody wants early trial assets.
Also China has been an area where LLY lacks, man those China patents look great huh?
Erbitux in NT219 trials, let's see what the Q2 acquisition was LLY."
"LLY CFO stating they are looking for early stage clinical and preclinical first in class assets to bolster their pipeline for 2025-2035 in major departments like Oncology.
Interesting because I was told by the Stocktwits scientist nobody wants early trial assets.
Also China has been an area where LLY lacks, man those China patents look great huh?
Erbitux in NT219 trials, let's see what the Q2 acquisition was LLY."
mal wieder etwas Substanzielles:
https://medicaid.nv.gov/Downloads/provider/E-Binder_SSSB_Sep…
Consensi auf dem Vormarsch in Nevada.
https://medicaid.nv.gov/Downloads/provider/E-Binder_SSSB_Sep…
Consensi auf dem Vormarsch in Nevada.
Durchsuchen
